Apple Tree Partners (ATP). a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy
Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute
ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells
Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer
Ascidian Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference